We carried out a meta-analysis of two recent psoriasis genome-wide association studies 1,2 with a combined discovery sample of 1,831 affected individuals (cases) and 2,546 controls. One hundred and two loci selected based on P value rankings were followed up in a three-stage replication study including 4,064 cases and 4,685 controls from Michigan, Toronto, Newfoundland and Germany. In the combined meta-analysis, we identified three new susceptibility loci, including one at NOS2 (rs4795067, combined P = 4 × 10 −11 ), one at FBXL19 (rs10782001, combined P = 9 × 10 −10 ) and one near PSMA6-NFKBIA (rs12586317, combined P = 2 × 10 −8 ). All three loci were also associated with psoriatic arthritis (rs4795067, combined P = 1 × 10 −5 ; rs10782001, combined P = 4 × 10 −8 ; and rs12586317, combined P = 6 × 10 −5 ) and purely cutaneous psoriasis (rs4795067, combined P = 1 × 10 −8 ; rs10782001, combined P = 2 × 10 −6 ; and rs12586317, combined P = 1 × 10 −6 ). We also replicated a recently identified 3 association signal near RNF114 (rs495337, combined P = 2 × 10 −7 ).
Psoriasis vulgaris (PsV) is one of several immunologically mediated disorders whose genetic provenance is now coming into focus. Although the most evident cellular features of psoriasis are epi dermal hyperplasia and altered keratinocyte differentiation, mount ing evidence implicates both innate and acquired immunity in disease pathogenesis 4 . About a third of the individuals with PsV develop psoriatic arthritis (PsA), an inflammatory arthritis that is usually sero negative for rheumatoid factor 5 . Herein, the abbreviation PsC refers to individuals with purely cutaneous psoriasis (that is, PsV without PsA), and the general term 'psoriasis' refers to PsV unless otherwise specified. Individuals with psoriasis are at significantly greater risk of cardiovascular morbidity and mortality than the general population, especially younger individuals with more severe skin disease 6 . Psoriasis is also associated with inflammatory bowel disease and other autoimmune disorders 7 .
Psoriasis is strongly influenced by genetic factors. The earliest reported genetic susceptibility factors for psoriasis map to the major histocompatibility complex (MHC) 8 and include haplotypes bearing HLA-Cw6 (ref. 9 ). More recently, the MHC component of susceptibility has been fine mapped to or very near HLA-Cw6 itself 10 , and genomewide association studies (GWAS) have identified nine additional regions outside the MHC with genomewide levels of statistical significance: IL12B, IL23R, IL23A, TNFAIP3, TNIP1, IL4-IL13, LCE3B-LCE3C, DEFB4 and SPATA2RNF114 (refs. 3, 11, 12) . In this study, we report the discovery of three new genetic suscepti bility loci for psoriasis, none of which have been definitively impli cated in any complex genetic disorder to date. We also replicate a previous report 3 of association to the SPATA2RNF114 locus (com bined P = 2 × 10 −7 ) and extend the associated region at this locus to include two additional candidate genes.
We augmented published GWAS results from the Collaborative Association Study of Psoriasis (CASP) 1 by using genotype imputa tion 13 to combine the results of that study with those of an independent GWAS of psoriasis from Kiel, Germany 2 using either phase 2 HapMap or 1000 Genomes Project haplotypes as a reference ( Supplementary  Table 1 ). Only SNPs imputed with relatively high confidence (esti mated r 2 between imputed and true genotypes >0.3) in both GWAS were considered for metaanalysis. Our discovery sample consisted of up to 1,831 cases and 2,546 controls with imputed genotypes for 2,502,313 (HapMap) or 7,456,344 (1000 Genomes Project) autosomal SNPs. Genomic control inflation factors for the P values from the metaanalysis of the CASP and Kiel GWAS were low (λ = 1.061 for HapMap and λ = 1.054 for 1000 Genomes Project imputations), and Genomewide association analysis identifies three psoriasis susceptibility loci l e t t e r s quantilequantile plots ( Supplementary Fig. 1 ) also indicated no substantial systematic differences between cases and controls due to cryptic relatedness, population substructure or other biases.
The replication sample consisted of up to 4,064 PsV cases and 4,685 controls from Michigan, Toronto, Newfoundland and Germany. All participating subjects gave informed consent and protocols were reviewed and approved by local institutional review boards. Ascertainment criteria for psoriasis have previously been described 10 . PsA was diagnosed according to the CASPAR criteria 14 . PsC was defined as the presence of skin lesions in the demonstrated absence of PsA at the time of recruitment in the study.
We selected 102 SNPs for replication based on their P value rank ings either in a subset of 350 CASP PsA cases compared to normal controls (53 SNPs referred to as set A; Supplementary Table 1 ) or in the combined CASPKiel GWAS (49 SNPs referred to as sets B and C; Supplementary Table 1 ). Imputation quality of these SNPs was generally excellent. In the firststage replication, we genotyped all selected SNPs in the large Michigan sample; 91 of these SNPs passed all quality control filters. In the secondstage replication, we typed all but one of the 51 quality control-filtered SNPs from set A of the PsA GWAS in the samples from Toronto and Newfoundland, which contained most of the PsA cases. SNPs with the most promising association results were then followed up with thirdstage typing, which consisted of eight SNPs from sets B and C in the two Canadian samples and six SNPs from all three sets in the German sample. Statistical significance of association was assessed with an allelic χ 2 test for experimentally genotyped SNPs and an equal variance t test with allele dosages for imputed SNPs. Meta analysis of association across cohorts incorporated both imputation quality and asymmetry in the number of cases and controls as well as the size of the cohort. See Online Methods for details of the quality control filters, imputation quality and metaanalysis.
We identified four SNPs at three loci for which association P values achieved genomewide statistical significance (P ≤ 5 × 10 −8 ) in the combined discovery and replication samples. Table 1 shows the results for these four SNPs along with three additional SNPs yielding a com bined P ≤ 1 × 10 −6 . Genotype counts for these seven SNPs are shown in Supplementary Table 2 . Results for the remaining SNPs passing quality control are summarized in Supplementary Table 3 , and asso ciation results for PsA compared to PsC are shown in Table 2 .
One of the associated SNPs (rs4795067, combined P = 4 × 10 −11 , replicationstage OR = 1.19) mapped to an intron of NOS2 ( Table 1) . As shown in Figure 1 , the strongest imputed association signals from the CASPKiel GWAS clustered in a region of low linkage disequilib rium (LD) containing no other genes. NOS2 encodes iNOS (inducible nitric oxide synthase), which is expressed by a subset of CD11c positive, CD1cnegative, TNFα (tumor necrosis factorα)producing inflammatory dendritic cells that is markedly expanded (30fold) in psoriatic lesions 15 . Consistent with this, in lesional psoriatic skin we found a 1.54fold overexpression of NOS2 mRNA by microarray ana lysis ( Supplementary Table 4 ) and a marked 16fold overexpression by QRTPCR ( Fig. 2 and Supplementary Table 5 ). However, neither rs4795067 nor any other SNP in this region was found to significantly a The number of cases and controls for the specified phenotype comparison that were genotyped and passed quality control for at least one of the 91 SNPs in the three replication sets. The actual numbers of cases and controls typed for each SNP varies and can be determined from the genotype counts in supplementary table 2. b Frequencies of the PsV risk allele for the two phenotypes being compared. Allele frequencies for the same phenotype (PsA, PsC or control) and the same SNP often differ among comparisons because of differing number of qualifying cohorts (for example, some cohorts have PsA but no PsC cases so qualify for PsA versus control but not PsA versus PsC or PsC versus control comparisons) and because variations in the proportions of each phenotype per cohort alter the relative cohort weights in the meta-analyses. l e t t e r s regulate NOS2 mRNA expression (that is, to function as a cisacting expression quantitative trait locus (ciseQTL)) as assessed by either microarray ( Supplementary Table 6 ) or qRTPCR assays (data not shown). Although this SNP attained genomewide significance only for PsC in a subphenotype analysis, it also yielded a strong association with PsA (OR = 1.23, P = 1 × 10 −6 ; Table 2 ). Notably similar to inflam matory dendritic cells in cutaneous psoriasis, cells infiltrating the sublining layer of diseased synovium express markedly higher levels of iNOS and TNFα in PsA than in osteoarthritis or traumatic arthri tis 16 . Although Online Mendelian Inheritance in Man (MIM163730) lists unconfirmed associations between NOS2 variants and malaria, mycetoma, preterm delivery and Parkinson's disease, this is the first description of a genomewide significant association between NOS2 and any complex genetic disorder. The next most significant SNP (rs10782001, combined P = 9 × 10 −10 , replication stage OR = 1.16) mapped to a large region of strong LD on chromosome 16p11.2 containing at least 31 genes ( Table 1 and Fig. 1) . Both rs10782001 and rs12924903, which are in strong LD with each other (r 2 = 1.0 in the phase 2 HapMap European CEU population), attained genomewide significance for PsA but not for PsC, despite the greater numbers of individuals with PsC (n = 2,113) relative to PsA (n = 1,361) ( Table 2) . Moreover, SNP rs10782001 was more strongly associated with PsA than with PsC at a statistically significant level (OR = 1.12, P = 0.02). Although any of the genes in the associated region could be respon sible for the observed association signal, POL3S and FBXL19 showed the strongest differential expression between psoriatic and normal skin (2.66fold increase for POL3S and a 1.43fold increase for FBXL19 in lesional skin compared to control skin; Fig. 1 and Supplementary  Table 4 ). POL3S encodes a secreted serine protease about which little is known 17 . FBXL19 is structurally related to FBXL11, an Fbox family member recently shown to inhibit NFκB (nuclear factor kappa light chain enhancer of activated B cells) activity by lysine demethylation 18 . Of the 68 human members of the Fbox protein family, only three (FBXL10, FBXL11 and FBXL19) have zinc finger, plant homology domain and leucinerich repeats in addition to the Fbox 19 . FBXL10 and FBXL11 con tain jumonji C domains known to be required for demethylase activity but FBLX19 does not 19 . Thus, FBXL19 might act as a dominant negative inhibitor of demethylase activity, thereby serving to activate NFκB.
The third associated SNP (rs12586317, combined P = 2 × 10 −8 , repli cation stage OR = 1.15; Table 1 ) mapped to the vicinity of NFKBIA, PSMA6 and KIAA0391. Imputation based on the 1000 Genomes Project led us to select this SNP for typing and revealed that the LGALS9
LGALS9
LGALS9 Figure 1 Evidence for psoriasis association in four genomic regions including the three new loci attaining genome-wide significance and the confirmed RNF114 region. The upper portion of each plot depicts association P values for a meta-analysis of the CASP and Kiel discovery GWAS using 1000 Genomes Project-based imputation and the lower portion depicts RefSeq genes and LD plots from the phase 2 HapMap CEU sample. For each region, the most strongly associated replicated SNP is highlighted in red, as are its P values for the discovery, replication and combined samples. l e t t e r s associated region extended to encompass NFKBIA, an observation that was not evident from HapMapbased imputation ( Fig. 1 and data not shown). Of these three genes, only PSMA6 is overexpressed in psoriatic lesions ( Fig. 2 and Supplementary Table 4 ). NFKBIA and PSMA6 are both attractive candidate genes for psoriasis suscep tibility, as NFKBIA encodes IκBα, an inhibitor of NFκB signaling, and PSMA6 encodes a proteosomal subunit involved in MHC class I antigen processing. Polymorphisms in both genes (MIM164008 and MIM602855) have been suggestively associated with susceptibility to various disorders including myocardial infarction, Graves' disease and inflammatory bowel disease. However, this is the first demonstra tion of a genomewide significant association in this region for any complex genetic disorder. Although they did not attain genomewide significance, SNPs rs1008953 (combined P = 1 × 10 −7 , replication stage OR = 1.14) and rs12580100 (combined P = 1 × 10 −6 , replication stage OR = 1.17) were also of interest. rs1008953 resides 3.7 kb upstream of SDC4, which encodes syndecan4, a cellsurface heparin sulfate proteoglycan that inhibits Tcell activation 20 . Expression of SDC4 mRNA was mark edly reduced in lesional psoriatic skin relative to both uninvolved and normal skin (Supplementary Tables 4 and 5) . However, there are several other genes under the association peak, and several SNPs in the region function as ciseQTLs for SYS1, DBNDD2, and PIGT expression ( Supplementary Table 6 and Supplementary Fig. 2) . rs12580100 resides 1.2 kb upstream of RPS26, which resides in a region that has been implicated in susceptibility to type 1 diabetes 21 and which encodes a ribosomal protein subunit whose expression is under cisacting genetic control in the liver 22 . rs12580100 lies only 300 kb from a confirmed association signal at rs2066808 near IL23A (ref. 1), but these association signals are at least partially independent because the two SNPs reside in different LD blocks ( Supplementary  Fig. 2) and show low pairwise LD (r 2 = 0.23), and a logistic regression model including both SNPs yielded significant partial association for each (P = 0.016 for rs12580100 and P = 3.0 × 10 −4 for rs2066808). Of note, we found that RPS26 is overexpressed in lesional psoriatic skin (Supplementary Tables 4 and 5) and confirm in skin that this region contains several highly significant eQTLs that clearly colo calize with the disease association signal for RPS26 but not for IL23A ( Supplementary Table 6 and Supplementary Fig. 2) .
Although also not reaching genomewide significance, rs495337 (combined P = 2 × 10 −7 , replication stage OR = 1.21) confirms previous reports of association between psoriasis and the SPATA2RNF114 region 3 . However, the 1000 Genomes Project-based imputation demonstrated that the region of association extends farther than previously reported and encompasses SLC9A8 and SNAI1 ( Fig. 1) . Of these four genes, RNF114 was the most strongly expressed in skin (Supplementary Table 4 ). None of the transcripts encoded by these four genes was increased in psoriatic lesions; one SPATA2 probe detected a 23% decrease ( Supplementary Table 4 ). We were unable to confirm a previous report of a ciseQTL in this region 3 , either by microarray ( Supplementary Table 6 ) or qRTPCR assays (data not shown); however, our gene expression sample was only about half the size of that used in the previous study.
Fine mapping studies are needed to identify causal variants in the three new susceptibility regions we have identified. Nevertheless, genes contained in these newly associated regions fit well with emerging concepts of psoriasis pathogenesis 12 . Given genetic, therapeutic and immunological results indicating that IL23 pro duced by dendritic cells promotes the survival and expansion of pathogenic Tcells in psoriasis 12 , it is noteworthy that one of our new regions contains NOS2, which is expressed by a massively expanded subset of TNFα producing inflammatory dendritic cells in psoriatic lesions 15 . Moreover, given that TNFAIP3 and TNIP1 regulate NFκB signaling and have been implicated in psoriasis susceptibility 1 , the fact that FBXL19 and NFKBIA regulate the same pathway further suggests the central importance of NFκB signaling in psoriasis. Finally, when combined with the profound response of PsA to TNFα blockers 4 and prior genetic results impli cating IL12B and TNIP1 in PsA susceptibility 1 , the identification of a new PsA susceptibility region containing FBXL19 suggests that this multicellular IL23/IL17/NFκB signaling circuit may also be of critical importance to the development of joint disease in individuals with psoriasis. 
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Genotyping. We determined genotypes for the discovery phase of the Collaborative Association Study of Psoriasis (CASP) on a Perlegen platform 1 and genotypes for the discovery phase of the Kiel GWAS on an Illumina HumanHap 550K array 2 . In Ann Arbor, followup genotyping was performed using either the TaqMan (Applied Biosystems) or the Sequenom MassArray (Sequenom) platforms. Additional followup genotyping was performed using the TaqMan platform in the samples from Kiel and the Sequenom platform in the samples from Newfoundland and Toronto.
Quality control filters. For the CASP and Kiel GWAS analyses, multiple qual ity control filters were applied to both the samples and the genotypes 1,2 . For the replication samples, we excluded SNPs with <95% genotyping call rates, with a Bonferonnicorrected Hardy Weinberg P < 0.05 or with cluster plots that did not show clear separation of the three genotype clusters. We also excluded samples with <95% genotyping call rate. For genotyping performed on the Sequenom platform, the sample filter was applied separately to each typing group (ranging from 15-23 SNPs in size). Sample and SNP filters were applied separately to each replication cohort.
Genotype imputation. We performed genotype imputation using a hidden Markov model algorithm implemented in MACH software version 1.0 as previously described 13, 23 . For replication sets A and B, we used HapMap 2 CEU phased haplotypes 24 , which serve as a good reference for populations of European descent 13, 25 . For replication set C, we used phased haplotypes from the August 2009 release of the 1000 Genomes Project as the reference. Parameters for the hidden Markov model for the 1000 Genomes Project imputation were first estimated using a subset of 250 randomly sampled individuals, and then all individuals were imputed based on those parameters. For both imputations, a dosage score (ranging from 0 to 2) was computed at each SNP for each indi vidual, which is the expected number of copies of a given allele conditional on the genotypes of directly assayed SNPs and integrating overall possible configu rations of the phased reference haplotypes. Imputed dosages for the two GWASs were analyzed separately, and the association test results were then combined by metaanalysis using the weighting scheme described below.
The predicted imputation quality of the 91 SNPs selected for replication was excellent; the median MACH r 2 values were 0.9858 and 0.9688, respectively, for the HapMap and 1000 Genomes Project imputations of the CASP GWAS, and 0.9887 and 0.9841 for the two imputations of the Kiel GWAS. We also tested the accuracy of MACH's predicted estimates of r 2 between imputed and true genotypes. All 91 replication SNPs were genotyped for a large subset of the CASP GWAS samples (456 of 1,359 cases and 670 of 1,400 controls), and six of these SNPs yielding significance at or near genomewide levels were also typed for a substantial subset of the Kiel GWAS samples (443 of 472 cases). A strong correspondence was seen between the observed and predicted squared correlation of imputed and experimentally determined genotypes for both the CASP GWAS (Pearson r = 0.914 for HapMap and r = 0.937 for 1000 Genomes Project imputations) and the Kiel GWAS (r = 1.000 for HapMap and r = 0.999 for 1000 Genomes Project).
Meta-analysis of association.
Evidence for association was combined across cohorts using a method adapted from published recommendations 26 . Signed z scores were calculated directly from association test statistics, with the sign of each z score indicating the direction of effect in that cohort. Z scores were then summed across multiple cohorts using weights equal to the square root of the effective sample size in each cohort divided by the sum of effective sample sizes in all cohorts, which ensures that the squared weights sum to one. The effective sample size (Ne) was determined for each combination of cohort and SNP by adjusting the raw sample size for asymmetry in the number of cases and controls and by scaling with the imputation uncertainty when applicable, as follows:
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here Na and Nu are the number of affected cases and unaffected controls typed or imputed for the given SNP in the given cohort, and MACH r 2 is an estimate of the squared Pearson correlation between the imputed genotype scores and the true genotypes for the given SNP. The first term on the right hand side of the equation calculates the symmetric casecontrol sample size yielding the same noncentrality parameter, and hence power, under the null hypothesis for an allelic association test of a biallelic marker, as does the given asymmetric casecontrol sample size. Under the alternative hypothesis of asso ciation, both the noncentrality parameter and N e depend upon not only N a and N u but also upon the genetic model (that is, the risk allele frequencies in cases and controls). However, for the effect sizes normally seen for complex disease loci (OR < 2.0), estimates of N e under the null and the alternative dif fer only modestly for a wide variety of genetic models, total sample sizes and N a to N u sample allocations. The second term on the righthand side of the equation downweights the contribution of a GWAS when a particular SNP was poorly imputed.
Estimates of odds ratios and allele frequencies were summed across multiple cohorts using the square of the weights described above. Odds ratios were first log transformed and then back transformed after summation across cohorts.
Quantile-quantile plots and genomic control for meta-analysis of CASP and Kiel GWAS.
Quantilequantile plots and genomic control inflation fac tors for the P values from a metaanalysis of the CASP and Kiel GWAS were restricted to those SNPs with a MACH r 2 imputation quality of at least 0.3 for both studies. The genomic control variance inflation factor (λ) was computed using the bounded median method 27 . Quantilequantile plots and genomic control λ values were determined both for all reliably imputed SNPs and after exclusion of SNPs within nine previously published regions of genomewide significant association with psoriasis. For the MHC, the excluded interval was the 7.7Mb extended region previously defined 28 . For regions harboring candidate loci IL12B, IL23R, IL23A, IL13, TNIP1 and TNFAIP3, boundaries of the excluded intervals were chosen as ± 500 kb relative to the most strongly associated SNP as previously determined 1 . Boundaries were also chosen to be ± 500 kb relative to the most strongly associated SNP in the RNF114 region 3 and ± 500 kb relative to the 32 kb deletion spanning the LCE3B and LCE3C genes on chromosome 1 29 . The published psoriasis locus that maps to a highly variable copy number variation near the βdefensin cluster on chromosome 8 was not excluded because there are no known SNPs in strong LD with this copy number variation 30 .
For the 1000 Genomes Project-based imputations, a 210 kb region on chro mosome 17p11.2 with multiple SNPs exhibiting strong but spurious associa tion was also excluded for one of the quantilequantile plots. These spurious associations are an artifact of a single SNP in the Kiel GWAS (rs4889730), which passed all quality control filters but was nevertheless unreliably typed as determined by post hoc inspection of the Illumina genotyping cluster plot. Removal of this SNP from the Kiel GWAS before reimputation resulted in loss of all evidence of association (data not shown). Notably, this region showed no evidence of association in the CASP GWAS, nor could observed associations in the Kiel GWAS be replicated for rs1975974 and rs17052344 in the Michigan sample ( Supplementary Table 3 ) or for rs17052344 in the German sample 2 .
Measurement and analysis of gene expression.
Six millimeter punch biopsies of normal skin (of unaffected individuals (74 subjects), as well as uninvolved skin and/or involved lesional skin of affected individuals (66 subjects), were obtained at the University of Michigan Department of Dermatology as previ ously described 31 . Involved skin biopsies were taken from psoriasis plaques, and uninvolved and normal skin were sampled from the buttocks at least 10 cm away from the nearest plaque. Study subjects did not use any systemic antipsoriatic treatments for 2 weeks prior to biopsy or topical antipsoriatic treatments for 1 week before biopsy. Informed consent was obtained from all subjects under protocols approved by the Institutional Review Board of the University of Michigan Medical School and the study was conducted according to the Declaration of Helsinki Principles. RNA from each biopsy was isolated using the RNeasy kit (Qiagen).
Samples for 64 normal skin biopsies and 58 paired affected and unin volved skin biopsies were run on Affymetrix U133 Plus 2.0 arrays accord ing to the manufacturer's protocol. The raw data were processed using the Robust Multichip Average (RMA) method, adjusting RMA expression values to account for batch and gender effects 31 . Gene expression was further assessed by qRTPCR, as described previously 31 , for 39 normal skin, 38 uninvolved skin and 37 lesional skin biopsies. These qRTPCR samples partially overlapped the microarray sample set (29 normal, 33 uninvolved and 29 affected skin samples common to both).
Two sample t tests were used to compare mean mRNA expression in skin from normal controls with that in lesional or nonlesional skin from indivi duals with psoriasis. For comparisons of mean expression in involved and uninvolved skin from affected individuals, paired t tests were used for micro array assays, as lesional and nonlesional skin was always sampled in pairs from each individual, but twosample t tests were used for qRTPCR assays because many of the affected individuals were biopsied for only lesional or nonlesional skin but not both. Log 2 transformed mRNA levels were used for all t tests.
For microarray data, we tested for cisacting expression quantitative trait loci (ciseQTL) separately in normal, uninvolved and involved skin. We used the score test in MERLIN (fastassoc option) to test cis associations between log 2 transformed mRNA levels of each probe (transcript) and SNPs in its cis candi date region, mapping from 1 Mb upstream of the transcription start site to 1 Mb downstream of the transcription end site. For genotyped SNPs, which were extracted from the CASP GWAS after quality control filtering, the observed number of copies of one allele was modeled. For imputed SNPs, which used HapMap2 CEU phased haplotypes as a reference, the dosage of one allele was modeled. Fiftyseven normal skin samples and fiftythree pairs of uninvolved and involved skin samples qualified for eQTL analysis, having both microarray expression profiling and genotype data. To increase power, a metaanalysis across independent skin samples (normal and uninvolved skin or normal and involved skin) was performed by combining sample size-weighted signed z scores for the individual skin types. Significance thresholds of 9 × 10 −7 , 1.0 × 10 −5 and 2.8 × 10 −5 , corresponding to false discovery rates of approxi mately 0.01, 0.05 and 0.10 were used to assess evidence for ciseQTLs.
For ciseQTL analyses using qRTPCR data, we used linear regression of mRNA levels against dosage of the risk allele. Combined analysis across inde pendent skin types was performed by including skin type as an independent indicator variable in the regression model. Thirtyseven normal skin, thirty seven uninvolved skin and 35 lesional skin samples qualified for analysis and had both qRTPCR expression and genotype data.
